JCM Webinar | HIV and Cardiovascular Disease: How Can We Face This Challenge?
27th September 2024
Welcome from the Chairs
Since the introduction of the first drugs for HIV infection, such as AZT, toxicity on the cardiovascular system has been demonstrated in people living with HIV (PWH). An association between myocardial infarction and combination antiretroviral therapy (cART) has been reported since 2004. Protease inhibitors and abacavir are some of the drugs that were associated with increased cardiovascular risk. The use of integrase Strand Transfer Inhibitors (INSTI) was also linked to increased cardiovascular events in a recent large study (RESPOND Cohort).
On the other hand HIV infection itself is one of the causes of increased inflammation and immune-activation, as demonstrated by the significant amount of cardiovascular events in the Strategy for Management of Antiretroviral Therapy (SMART) trial within the PWH group that stopped cART. However, studies on immune activation have also demonstrated that PWH is a marker of T cell activation and senescence that could predict atherosclerosis.
In 2013, HIV infection was recognized as an independent risk factor for myocardial infarction, also followed by the demonstration of an independent association with stroke and peripheral artery disease.
Premature aging in PWH is another factor that deeply influences cardio-metabolic function in addition to a high prevalence of dyslipidemia and hypertension in PWH.
HIV specialists need the support of cardiologists to understand how to check and diagnose early damage to the heart in PWH. At the same time, specialists in metabolic abnormalities could suggest how and when to treat dyslipidemia and impaired fasting glucose in PWH. Conversely, cardiologists and diabetologists should be aware of complications due to HIV and cART.
We are very much looking forward to seeing you at the JCM Webinar | HIV and Cardiovascular Disease: How can we face this Challenge?"
Date: 27 September 2024
Time: 4:30pm - 6.00pm CEST
Webinar ID: 819 0073 0401
Webinar Secretariat: journal.webinar@mdpi.com
Event Chairs
Dr. Diego Ripamonti graduated with honors in medicine and surgery from the University of Brescia. He then obtained the specialization in infectious diseases at the University of Brescia. Since 2000 he has worked as an ID consultant in the ID unit with multidisciplinary expertise. Since 2015 he has been deputy director of the ID unit at ASST Papa Giovanni XXIII. he is responsible for the control of the DRG-related hospital discharge. Member of SMIT and ICAR, his research activity focuses on HIV and infectious diseases.
Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
Dr Nicola Squillace is an infectious diseases specialist with long-standing experience in the management of HIV infection. He attained his specialization in infectious diseases at University of Modena and Reggio Emilia in 2005, and since that time he has been involved in the treatment of HIV infection and the evaluation of adverse drug reactions and toxicity related to combination antiretroviral treatment (cART). He has worked for 3 years at the Metabolic Clinic of Modena University Hospital in the diagnosis and treatment of lipodystrophy and other toxicity related to cART. Since 2008, he has worked at Fondazione IRCCS San Gerardo dei Tintori in Monza in an outpatients’ clinic that includes about 1500 people living with HIV (PWH). His expertise includes the management and prevention of cardiovascular disease, dyslipidemia, and metabolic syndrome in PWH, and the management and prevention of HPV infection and anal cancer in PWH. He has also been involved in the diagnosis and prevention of other comorbidities in PWH such as renal, bone, and liver toxicities. He recently promoted a multicenter study on the prevalence and progression of hepatic steatosis in PWH. In recent years, he has been involved in the pre-exposure prophylaxis (PREP) for HIV program in Itay, the diagnosis and treatment of sexually transmitted infections, and SARS-CoV-2 infection and its complications. He is a member of the scientific committee of the Italian Cohort Naïve to Antiretrovirals (ICONA) study and the Surveillance Cohort Long-term Toxicity Antiretrovirals (SCOLTA/CISAI) group.
Invited Speakers
Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy
HIV and Cardiovascular Risk: Is the Virus or the Therapy?
Jovana Milic, MD, PhD, has been working at the University of Modena and Reggio Emilia (UNIMORE), Italy, since 2018. She graduated from the Faculty of Medicine, University of Belgrade, in 2016 and completed a PhD in Clinical and Experimental medicine in 2021 at the UNIMORE. Her research focused on key relationships between non-alcoholic fatty liver disease, insulin resistance, diabetes, frailty, weight gain, and integrase inhibitor-based regimens in people living with HIV. Dr Milic is actively involved in the work of the Modena HIV Metabolic Clinic, which provides comprehensive, multi-dimensional, and multidisciplinary assessment of people living with HIV, particularly focusing on patients over 65 who undergo a dedicated screening for geriatric syndromes and frailty. Dr. Milic's particular focus is on non-invasive diagnostics and management of metabolic-associated steatotic liver disease (MASLD) in people with HIV. She has been also involved in cardiovascular risk assessment by measuring arterial stiffness and its association with the development of subclinical and clinical cardiovascular disease in people living with HIV. Dr Milic has been also involved in the management of COVID-19 epidemic in Modena. She has been a member of the Modena COVID-19 Working Group (MoCo19), collaborating in several trials on this topic. Dr Milic has published over 90 peer-reviewed papers (current H-index 21) and serves as a reviewer for several infectious diseases and geriatrics journals.
School of Medicine, Department of Medicine and Surgery, University of Milano Bicocca, Italy
Management of Dyslipidemia and Prevention of Diabetes in People Living with HIV
Roberto Trevisan, MD, PhD, is an Associate Professor of Endocrinology at School of Medicine, University of Milano Bicocca, and the Head of Endocrinology and Diabetes Unit, ASST Papa Giovanni XXIII. He trained in Endocrinology at the University of Padua, and completed his PhD in Internal Medicine at the University of Padua and University of Modena. Dr. Trevisan has been an Honorary Professor of Diabetes at University of Padua, the Secretary of the European Study Group for the Study of Diabetic Nephropathy, and the President for the region of Lombardia of Italian Society of Diabetology. He is a member of the Scientific Council of the Italian Society of Diabetology and National Executive Committee of Italian Society of Diabetology. Dr. Trevisan’s major research interests are the study of diabetic nephropathy, diabetic vascular complications, and insulin resistance in people with diabetes. Furthermore, another field of research is the advanced options for insulin therapy (CSII, CGMS, and pancreas transplantation). He has published more than 200 original papers in international peer reviewed journals on these topics.
School of Medicine, University of California San Francisco (UCSF), Zuckerberg San Francisco General Hospital, San Francisco, California, USA
Cardiovascular Disease and HIV: Understanding the Link and Optimizing the Diagnostic Strategies
Priscilla Hsue is a Professor at the School of Medicine, University of California (UC), San Francisco. She trained in Internal Medicine in the Molecular Medicine Training Program at UC San Francisco and in Cardiovascular Medicine at UC San Francisco. She served as Chief Cardiology Fellow during this time. She has been on the faculty in the Department of Medicine at San Francisco General Hospital since 2002. She started working with the HIV Cardiology Clinic in March 2004 at the Positive Health Program at Ward 86, which is one of the first subspeciality clinics of its kind in the nation. She has conducted several investigations into the pathogenesis of atherosclerosis and the incidence and mechanisms of pulmonary hypertension in people living with HIV (PWH) treated with antiretroviral therapy. She described clinical features and outcomes of acute coronary syndromes in PWH and explored the management of dyslipidemia in PWH. She also studies immune activation as a cause of early atherosclerosis in PWH. In recent years, she has studied the effects of SARS-CoV-2 infection and post-COVID conditions on the cardiovascular system. She is one of the most updated cardiologists in the management and prevention of cardiovascular disease in PWH.
Registration
This is a free webinar. After registration, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Unable to attend? Register anyway and we will let you know when the recording is available for viewing.
Program
|
Speaker |
Time in CEST |
|
Dr. Diego Ripamonti and Dr. Nicola Squillace (Chairs) Introduction |
4:30 - 4:40 pm |
|
Dr. Jovana Milic HIV and Cardiovascular Risk: Is the Virus or the Therapy? |
4:40 - 5:00 pm |
|
Prof. Roberto Trevisan Management of Dyslipidemia and Prevention of Diabetes in People Living with HIV |
5:00 - 5:20 pm |
|
Prof. Dr. Priscilla Hsue Cardiovascular Disease and HIV: Understanding the Link and Optimizing Diagnostic Strategies |
5:20 - 5:40 pm |
|
Discussion Session |
5:40 - 5:55 pm |
|
Dr. Diego Ripamonti and Dr. Nicola Squillace (Chairs) Closing of Webinar |
5:55 - 6:00 pm |
Relevant Special Issue
Heart Disease Complicated by HIV Infection: Predictors, Diagnosis and Treatment Options
Edited by Dr. Diego Ripamonti
Deadline for submission: 20 December 2024
Sponsors and Partners
Organizers
